King Pharma - Comparative Multiple Analysis

King Pharma (Comparative Multiple Analysis)

placeholder_large_analysis.png

Notes on the Comparative Multiple Analysis of King Pharma

WikiWealth compares King Pharma's revenue, EBITDA, and EBIT multiples to their peers in order to determine the appropriate fair valuation. Click in the top right corner to experiment with King Pharma's comparative analysis.

Notes from the analysis:

1. WikiWealth uses quantitative measures to determine the multiple range for King Pharma.
2. Free cash flow to the firm (FCF) multiple is free cash flow to equity holders plus interest owed to King Pharma's debt holders.
3. Multiples incorporate benefits due to economies of scale; WikiWealth compares absolute enterprise value multiples to competitor's multiples.
4. WikiWealth excludes outliers when calculating individual company multiples.

Helpful Information for King Pharma's Analysis


How does this work? The Comparative Investment Analysis determines the value of King Pharma by comparing King Pharma financial ratios, prices, growth rates, margins, etc. to those of relevant peer groups.

Value Investing Importance? This method is widely used by investment professionals to determine the correct price of investments, especially initial public offerings (IPOs). It is one element of WikiWealth's three Wall Street approaches used to determine the correct fair value of King Pharma.

See the King Pharma cash flow (DCF) analysis for a completely different approach that's popular on Wall Street for determining the value of an investment in King Pharma.

Also, see the King Pharma's buffett intrinsic valuation analysis for WikiWealth's attempt to replicate the investing formula's used by Warren Buffett and King Pharma's valuation conclusion for a quick summary.